Listed

Ironwood Pharmaceuticals Inc

IRWDNasdaqCIK 1446847HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$113.0mRevenue, Q2 FY2026, three months to 2026-06-30$113.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091987.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 6, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$113.0mRevenue, Q2 FY2026, three months to 2026-06-30$113.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091987.Report this figure+32.6% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin70.2%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $79.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091987.Revenue: $113.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091987.Report this figure+17.0 pts on a year earlier
  • Net margin45.4%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $51.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091987.Revenue: $113.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091987.Report this figure+17.7 pts on a year earlier
  • Diluted EPS$0.31Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-091987.Report this figure+121.4% on a year earlier
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$113.0mOperating margin 70.2%
Diluted EPS$0.31, Q2 FY2026
Free cash flow$74.6m, Q4 FY2025
Ironwood Pharmaceuticals Inc, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m91.6Revenue, Q3 FY2024, three months to 2024-09-30$91.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure90.5Revenue, Q4 FY2024, three months to 2024-12-31$90.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure41.1Revenue, Q1 FY2025, three months to 2025-03-31$41.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-057110.Report this figure85.2Revenue, Q2 FY2025, three months to 2025-06-30$85.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091987.Report this figure122Revenue, Q3 FY2025, three months to 2025-09-30$122.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure47.7Revenue, Q4 FY2025, three months to 2025-12-31$47.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure107Revenue, Q1 FY2026, three months to 2026-03-31$106.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-057110.Report this figure113Revenue, Q2 FY2026, three months to 2026-06-30$113.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091987.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%28.0%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $25.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001104659-25-108795.Revenue: $91.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure34.8%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $31.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020489. Derived: 12-month figure less the 9-month figure.Revenue: $90.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure(70.7%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$29.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-057110.Revenue: $41.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-057110.Report this figure53.2%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $45.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091987.Revenue: $85.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091987.Report this figure61.8%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $75.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-10, accession 0001104659-25-108795.Revenue: $122.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure14.3%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $6.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020489. Derived: 12-month figure less the 9-month figure.Revenue: $47.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure68.1%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $72.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-057110.Revenue: $106.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-057110.Report this figure70.2%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $79.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091987.Revenue: $113.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091987.Report this figure
Net margin%4.0%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $3.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020489.Revenue: $91.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure2.5%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $2.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020489.Revenue: $90.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure(90.9%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$37.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-057110.Revenue: $41.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-057110.Report this figure27.7%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $23.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091987.Revenue: $85.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091987.Report this figure32.8%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $40.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020489.Revenue: $122.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure(4.8%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$2.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020489.Revenue: $47.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure38.3%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $40.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-07, accession 0001104659-26-057110.Revenue: $106.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001104659-26-057110.Report this figure45.4%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $51.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001104659-26-091987.Revenue: $113.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001104659-26-091987.Report this figure
Diluted EPS$ per share0.02Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure0.01Diluted EPS, Q4 FY2024, three months to 2024-12-31$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure(0.23)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-057110.Report this figure0.14Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-091987.Report this figure0.23Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure(0.01)Diluted EPS, Q4 FY2025, three months to 2025-12-31−$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure0.24Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.24 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001104659-26-057110.Report this figure0.31Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001104659-26-091987.Report this figure
Free cash flow$m9.9Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $9.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001104659-25-108795. Derived: 9-month figure less the 6-month figure.Capital expenditure: $16.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001104659-25-108795. Derived: 9-month figure less the 6-month figure.Report this figure15.2Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $15.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001104659-26-020489. Derived: 12-month figure less the 9-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001104659-26-020489. Derived: 12-month figure less the 9-month figure.Report this figure19.9Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $20.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001104659-26-057110.Capital expenditure: $31.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001104659-26-057110.Report this figure(15.1)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$15.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001104659-26-091987. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001104659-26-091987. Derived: 6-month figure less the 3-month figure.Report this figure47.6Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $47.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-10, accession 0001104659-25-108795. Derived: 9-month figure less the 6-month figure.Capital expenditure: $2.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-10, accession 0001104659-25-108795. Derived: 9-month figure less the 6-month figure.Report this figure74.6Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $74.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001104659-26-020489. Derived: 12-month figure less the 9-month figure.Capital expenditure: −$1.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001104659-26-020489. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$296.2mOperating margin 33.3%
Diluted EPS$0.15, FY2025
Free cash flow$127.0m, FY2025
Ironwood Pharmaceuticals Inc, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m414Revenue, FY2021, twelve months to 2021-12-31$413.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-16, accession 0001558370-24-001275.Report this figure411Revenue, FY2022, twelve months to 2022-12-31$410.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-31, accession 0001558370-25-004072.Report this figure443Revenue, FY2023, twelve months to 2023-12-31$442.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-31, accession 0001558370-25-004072.Report this figure351Revenue, FY2024, twelve months to 2024-12-31$351.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure296Revenue, FY2025, twelve months to 2025-12-31$296.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%56.1%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $232.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-16, accession 0001558370-24-001275.Revenue: $413.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-16, accession 0001558370-24-001275.Report this figure61.0%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $250.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-31, accession 0001558370-25-004072.Revenue: $410.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-31, accession 0001558370-25-004072.Report this figure(213.5%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$945.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-31, accession 0001558370-25-004072.Revenue: $442.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-31, accession 0001558370-25-004072.Report this figure26.5%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $93.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020489.Revenue: $351.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure33.3%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $98.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020489.Revenue: $296.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure
Net margin%127.7%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $528.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-16, accession 0001558370-24-001275.Revenue: $413.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-16, accession 0001558370-24-001275.Report this figure42.6%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $175.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-31, accession 0001558370-25-004072.Revenue: $410.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-31, accession 0001558370-25-004072.Report this figure(226.4%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$1.00bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-31, accession 0001558370-25-004072.Revenue: $442.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-31, accession 0001558370-25-004072.Report this figure0.3%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $880.0k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020489.Revenue: $351.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure8.1%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $24.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001104659-26-020489.Revenue: $296.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure
Diluted EPS$ per share3.21Diluted EPS, FY2021, twelve months to 2021-12-31$3.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-16, accession 0001558370-24-001275.Report this figure0.96Diluted EPS, FY2022, twelve months to 2022-12-31$0.96 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-31, accession 0001558370-25-004072.Report this figure(6.45)Diluted EPS, FY2023, twelve months to 2023-12-31−$6.45 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-31, accession 0001558370-25-004072.Report this figure0.01Diluted EPS, FY2024, twelve months to 2024-12-31$0.01 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure0.15Diluted EPS, FY2025, twelve months to 2025-12-31$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure
Free cash flow$m262Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $261.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-16, accession 0001558370-24-001275.Capital expenditure: $265.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-16, accession 0001558370-24-001275.Report this figure274Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $273.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-31, accession 0001558370-25-004072.Capital expenditure: $136.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-31, accession 0001558370-25-004072.Report this figure183Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $183.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-31, accession 0001558370-25-004072.Capital expenditure: $273.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-31, accession 0001558370-25-004072.Report this figure103Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $103.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001104659-26-020489.Capital expenditure: $142.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure127Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $127.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001104659-26-020489.Capital expenditure: $34.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001104659-26-020489.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Dec 2024 to Nov 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Ironwood Pharmaceuticals Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$74.9m17,788,557Added+4,425,627
ARMISTICE CAPITAL, LLC2026-06-30$58.7m13,932,000Reduced−1,096,000
Sarissa Capital Management LP2026-06-30$38.7m9,188,635Unchanged
STATE STREET CORP2026-06-30$37.1m8,809,601Added+1,352,657
BANK OF AMERICA CORP /DE/2026-06-30$36.6m8,683,803Added+896
RENAISSANCE TECHNOLOGIES LLC2026-06-30$33.7m7,993,226Reduced−67,847
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$27.8m6,608,508Added+511,054
AQR CAPITAL MANAGEMENT LLC2026-06-30$27.2m6,465,921Reduced−1,069,159
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$23.2m5,513,355Reduced−1,168,682
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$20.3m4,831,657Added+288,135

Recent filings

All 1,404 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Ironwood Pharmaceuticals Inc, recent filings
FiledFormWhat it isAccession number
2026-10-1611:30 ET8-K5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits0001104659-26-116423
2026-08-0620:07 ET10-QQuarterly reportPeriod 2026-06-300001104659-26-091987
2026-08-0611:12 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-26-091625
2026-06-1820:14 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001104659-26-075730
2026-06-1520:05 ET8-K8.01 Other events0001104659-26-074023
2026-05-2120:05 ET8-K/A5.02 Departure or appointment of officers or directors0001104659-26-065140
2026-05-1312:00 ET8-K5.02 Departure or appointment of officers or directors0001104659-26-059814
2026-05-0720:08 ET10-QQuarterly reportPeriod 2026-03-310001104659-26-057110
2026-05-0711:10 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001104659-26-056656
2026-04-2820:06 ETDEF 14AProxy statementPeriod 2026-06-160001104659-26-050325

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1446847
Tickers
IRWD
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Accelerated filer<br>Smaller reporting company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:40 ET. Listed shows no prices and gives no investment advice.